Video

VIDEO: Secukinumab ‘exciting’ new agent for psoriasis


 

AT SDEF HAWAII DERMATOLOGY SEMINAR

References

KAUAI, HAWAII – The Food and Drug administration recently approved a new class of drug for psoriasis. Secukinumab, indicated for the treatment of mild to severe psoriasis, targets IL-17, a cytokine highly implicated in the disease.

“I’m very excited to try this drug in my patients,” Dr. Kristina Callis Duffin said at the Hawaii Dermatology Seminar sponsored by Global Academy for Medical Education/Skin Disease Education Foundation.

In this report, Dr. Duffin of the University of Utah explains the drug’s mechanism of action, describes how it differs from other biologic agents used to treat psoriasis, and shares promising data showing improved scores on the Psoriasis Area and Severity Index (PASI).

SDEF and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Recommended Reading

Manage Your Dermatology Practice: Managing Difficult Patient Encounters
MDedge Dermatology
Survey: Psoriasis/psoriatic arthritis undertreated
MDedge Dermatology
Most cost-effective psoriasis treatment: methotrexate
MDedge Dermatology
Infliximab most common cause of drug-induced liver injury
MDedge Dermatology
Unique psoriatic arthritis genetic risk loci discovered
MDedge Dermatology
VIDEO: As biosimilars arrive in U.S., treatment questions arise
MDedge Dermatology
Counting Costs
MDedge Dermatology
Ixekizumab improves lesions in patients with chronic plaque psoriasis after 20 weeks
MDedge Dermatology
Data suggest link between tonsillectomy, psoriasis improvement
MDedge Dermatology
New psoriasis drugs offer treatment advantages
MDedge Dermatology